The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk stock jumped Wednesday on better-than-expected fourth-quarter sales, helped by an Ozempic beat.

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy doubled in the fourth quarter, but the Danish ...